118 related articles for article (PubMed ID: 10589231)
1. [Irregular blood group antibodies during pregnancy: screening is mandatory].
van der Does JA
Ned Tijdschr Geneeskd; 1999 Nov; 143(46):2342. PubMed ID: 10589231
[No Abstract] [Full Text] [Related]
2. [Irregular blood group antibodies during pregnancy: screening is mandatory].
Semmekrot BA; de Man AJ; Boekkooi PF; van Dijk BA
Ned Tijdschr Geneeskd; 1999 Jul; 143(28):1449-52. PubMed ID: 10443258
[TBL] [Abstract][Full Text] [Related]
3. Effect of screening for red cell antibodies, other than anti-D, to detect hemolytic disease of the fetus and newborn: a population study in the Netherlands.
Koelewijn JM; Vrijkotte TG; van der Schoot CE; Bonsel GJ; de Haas M
Transfusion; 2008 May; 48(5):941-52. PubMed ID: 18248570
[TBL] [Abstract][Full Text] [Related]
4. [Irregular blood group antagonisms].
Heringa MP; Waelput AJ; Flikweert S
Ned Tijdschr Geneeskd; 1999 Sep; 143(38):1933-4. PubMed ID: 10526625
[No Abstract] [Full Text] [Related]
5. Implementation of routine screening for Kell antibodies: does it improve perinatal survival?
Kamphuis MM; Lindenburg I; van Kamp IL; Meerman RH; Kanhai HH; Oepkes D
Transfusion; 2008 May; 48(5):953-7. PubMed ID: 18248569
[TBL] [Abstract][Full Text] [Related]
6. An unusual case of isoimmunization by D, Cellano (k) and Duffy (Fyb) antigens.
Chojnacka-Jachimiak I; Seyfried H; Koziołowa H
Arch Immunol Ther Exp (Warsz); 1971; 19(5):585-91. PubMed ID: 4952639
[No Abstract] [Full Text] [Related]
7. [Blood group immunization during pregnancy in Netherlands].
Heringa MP; Waelput AJ; Flikweert S
Ned Tijdschr Geneeskd; 2000 Feb; 144(9):454-5. PubMed ID: 10719560
[No Abstract] [Full Text] [Related]
8. Kell alloimmunization in pregnancy: associated with fetal thrombocytopenia?
van den Akker ES; Klumper FJ; Brand A; Kanhai HH; Oepkes D
Vox Sang; 2008 Jul; 95(1):66-9. PubMed ID: 18435678
[TBL] [Abstract][Full Text] [Related]
9. Pregnancy outcome in mothers who develop Kell antibodies.
Farr V; Gray E
Scott Med J; 1988 Aug; 33(4):300-3. PubMed ID: 3055288
[TBL] [Abstract][Full Text] [Related]
10. Blood transfusion: the hidden dangers.
Anderson T
Pract Midwife; 2004 Mar; 7(3):12-6. PubMed ID: 15058056
[No Abstract] [Full Text] [Related]
11. Two additional examples of non-transfusion-stimulated anti-Kell.
Clark A; Monaghan WP; Martin CA
Am J Med Technol; 1981 Dec; 47(12):983-4. PubMed ID: 7332023
[TBL] [Abstract][Full Text] [Related]
12. Experiences with fetomaternal alloimmune thrombocytopenia in the Netherlands over a 2-year period.
Serrarens-Janssen VM; Steegers EA; van den Bos A; van Heijst AF; Pereira R; Semmekrot BA
Acta Obstet Gynecol Scand; 2005 Feb; 84(2):203; author reply 204. PubMed ID: 15683387
[No Abstract] [Full Text] [Related]
13. Anti-Kell in pregnancy and hydrops fetalis.
Goh JT; Kretowicz EM; Weinstein S; Ramsden GH
Aust N Z J Obstet Gynaecol; 1993 May; 33(2):210-1. PubMed ID: 8216130
[No Abstract] [Full Text] [Related]
14. Blood spot screening. Interview by Dina Leifer.
Anionwu E
Nurs Stand; 2004 Nov 3-9; 19(8):16-7. PubMed ID: 15552462
[No Abstract] [Full Text] [Related]
15. Response to the international forum on haemovigilance.
Wiersum-Osselton JC; Schipperus MR
Vox Sang; 2006 Oct; 91(3):278-9. PubMed ID: 16958843
[No Abstract] [Full Text] [Related]
16. [A pregnant woman with irregular erythrocyte antibodies for whom no compatible packed red blood cells were available].
Boonstra JG; Overbeeke MA; de Rijke YB; Duvekot JJ
Ned Tijdschr Geneeskd; 2005 Nov; 149(47):2633-6. PubMed ID: 16355577
[TBL] [Abstract][Full Text] [Related]
17. Kell sensitization in pregnancy.
Bowman JM
Am J Obstet Gynecol; 1986 Oct; 155(4):912-4. PubMed ID: 3766648
[No Abstract] [Full Text] [Related]
18. Dangers of anti-Kell in pregnancy.
Lancet; 1991 Jun; 337(8753):1319-20. PubMed ID: 1674303
[No Abstract] [Full Text] [Related]
19. Re: Prediction of the fetal Kell blood group reduces aggressive interventions.
Araújo F; Monteiro F; Pereira C; Duran J; Nascimento H; Lima L; Cunha A; Storry J; Guimarães J
Aust N Z J Obstet Gynaecol; 2005 Oct; 45(5):464. PubMed ID: 16171491
[No Abstract] [Full Text] [Related]
20. Develop a useful donor-screening process.
Harty-Golder B
MLO Med Lab Obs; 2003 Oct; 35(10):34. PubMed ID: 14571850
[No Abstract] [Full Text] [Related]
[Next] [New Search]
